The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

Daiichi Sankyo and AstraZeneca will share equally development and commercialization costs as well as profits from DS-1062 worldwide, except for Japan.

- Collaboration combines Daiichi Sankyo's scientific and technological excellence with AstraZeneca's global experience and resources in oncology to accelerate and expand the potential of [fam ...

MADRID—Daiichi Sankyo and ADC partner AstraZeneca finally have some clarity on the deaths that occurred in a pair of phase 3 studies for their Enhertu follow up Dato-DXd.

Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant and clinically meaningful improvement in main goal for its gastric or ...

AstraZeneca and Daiichi Sankyo have not released full safety data from the TROPION-Lung04 cohorts but said there were no new safety signals and no grade 5 ILD events—meaning no deaths from this ...

AstraZeneca and Daiichi Sankyo said the improvement in progression-free survival was observed across all pre-specified patient subgroups that received Enhertu paired with Perjeta.

AstraZeneca, Daiichi Sankyo win first U.S. approval for key cancer drug. AstraZeneca has forecast peak annual sales of the drug, to be marketed as Datroway, at more than $5 billion.

Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU (a HER2 directed ADC) in March 2019, and DS-1062 (a TROP2 directed ADC) in July 2020 ...

Daiichi Sankyo and AstraZeneca will jointly develop and commercialize DS-1062 worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will manufacture and ...